51. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
- Author
-
Annese, Vito, Beaugerie, Laurent, Egan, Laurence, Biancone, Livia, Bolling, Claus, Brandts, Christian, Dierickx, Daan, Dummer, Reinhard, Fiorino, Gionata, Gornet, Jean Marc, Higgins, Peter, Katsanos, Konstantinos H., Nissen, Loes, Pellino, Gianluca, Rogler, Gerhard, Scaldaferri, Franco, Szymanska, Edyta, Eliakim, Rami, Bossuyt, P., Bogut, A., Krznaric, Z., Mijandrusic Sincic, B., Bortlik, M., Douda, T., Knudsen, T., Manninen, P., Nieminen, U., Kucharzik, T., Siegmund, B., Koutroubakis, I., Epameinondas, T., Lakatos, P., Waterman, M., Kohn, A., Goll, Null, Kierkus, J., Zagorowicz, E., Diculescu, M. M., Tarabar, D., Drobne, D., Gisbert, J., Strid, H., Pierik, M., Celik, A. F., Irving, P., Marshall, J., Riis, L., Amiot, A., Mantzaris, G., Sinagra, E., Sampietro, G., D'Incà, R., De Ridder, L., Nunesl, P. B., Marin Jimenez, I., Ramirez, V. H., Juillerat, P., Claridge, A., Macdonald, J., Rieder, F., SELVAGGI, Francesco, University of Zurich, Annese, Vito, Bossuyt, Peter, Beaugerie, Laurent, Egan, Laurence, Biancone, Livia, Bolling, Clau, Brandts, Christian, Dierickx, Daan, Dummer, Reinhard, Fiorino, Gionata, Gornet, Jean Marc, Higgins, Peter, Katsanos, Konstantinos H., Nissen, Loe, Pellino, Gianluca, Rogler, Gerhard, Scaldaferri, Franco, Szymanska, Edyta, Eliakim, Rami, Bossuyt, P., Bogut, A., Krznaric, Z., Mijandrusic Sincic, B., Bortlik, M., Douda, T., Knudsen, T., Manninen, P., Nieminen, U., Kucharzik, T., Siegmund, B., Koutroubakis, I., Epameinondas, T., Lakatos, P., Waterman, M., Kohn, A., Goll, Null, Kierkus, J., Zagorowicz, E., Diculescu, M. M., Tarabar, D., Drobne, D., Gisbert, J., Strid, H., Pierik, M., Celik, A. F., Irving, P., Marshall, J., Riis, L., Amiot, A., Mantzaris, G., Sinagra, E., Selvaggi, Francesco, Sampietro, G., D'Incà, R., De Ridder, L., Nunesl, P. B., Marin Jimenez, I., Ramirez, V. H., Juillerat, P., Claridge, A., Macdonald, J., and Rieder, F.
- Subjects
medicine.medical_specialty ,Evidence-based practice ,Prognosi ,Alternative medicine ,MEDLINE ,610 Medicine & health ,Malignancy ,Inflammatory bowel disease ,Risk Factors ,Neoplasms ,medicine ,Humans ,2715 Gastroenterology ,Settore MED/12 - Gastroenterologia ,Evidence-Based Medicine ,business.industry ,Risk Factor ,Medicine (all) ,Inflammatory Bowel Disease ,Gastroenterology ,10177 Dermatology Clinic ,Cancer ,General Medicine ,Evidence-based medicine ,Inflammatory Bowel Diseases ,Prognosis ,medicine.disease ,Ulcerative colitis ,Europe ,10219 Clinic for Gastroenterology and Hepatology ,Family medicine ,Immunology ,Neoplasm ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Human - Abstract
The global prevalence of cancer is increasing, largely as more patients are living into old age. Therefore, gastroenterologists caring for patients with inflammatory bowel disease [IBD] increasingly are managing patients with cancer, or a previous history of cancer. This often requires joint management with the patient’s oncologist, enabling case-by-case decision-making based on the characteristics and expected evolution of the index cancer. Previously, no European guidelines existed describing the impact of IBD on malignancy. For this reason, the European Crohn’s and Colitis Organisation [ECCO] Guidelines Committee [GuiCom] decided to elaborate a set of Consensus Statements on optimal risk/benefit strategies for treating IBD patients with cancer or a history of cancer. The development of clinical practice guidelines is expensive and time consuming, and it is the Committee’s hope that these statements will facilitate and accelerate future efforts to elaborate formal guidelines, providing useful information on areas for which evidence is lacking and where controlled studies are needed. The strategy used to produce the Consensus Statements involved five steps: 1. Two members of Guicom [VA and RE] identified four main topics that needed to be addressed: a] IBD and solid tumours; b] IBD and skin and haematological malignancies; c] malignancy related to therapy: risk and prevention; and d] management of IBD patients with a history of malignancy. During 2014, calls for participation in the drafting of consensus statements were issued to ECCO members, and selected oncologists known for their expertise and active research in the field were invited to join the Consensus. Participants were selected by the Committee, and four working groups were created, each composed of a chairperson [LE, RE, LB, and VA], two ECCO members including young members [Y-ECCO], and one or two experienced oncologists. The chairmen and their groups elaborated relevant questions on topics dealing with current practice and/or areas …
- Published
- 2015